LRRK2 Kinase Inhibition via Rubicon Phosphorylation Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for Parkinson's disease (PD) are inadequate, relying on motor symptoms and brain scans without a specific diagnostic assay, and there is a need for effective treatments targeting Leucine-rich repeat kinase 2 (LRRK2) associated diseases.
Innovation Solution
Development of an in vitro method to detect the phosphorylation of Rubicon protein at Threonine 166 using specific antibodies, as well as inhibitors that block the interaction between LRRK2 and Rubicon, to aid in diagnosis and treatment of LRRK2-associated diseases such as PD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic methods relying on motor symptoms and brain scans are used, then diagnosis can be performed without specific assays, but diagnostic accuracy and early detection capability are insufficient
Solution Approach 1:
The patent replaces complex imaging and clinical observation systems with a biochemical detection system based on ELISA assays. The mechanical/visual diagnostic process (brain scans and motor symptom observation) is substituted with an immunological chemical system that uses antibodies to detect phosphorylated Rubicon protein, providing more precise and objective measurement of LRRK2 activity.
Solution Approach 2:
The patent introduces phosphorylated Rubicon protein as an intermediary biomarker that mediates between LRRK2 kinase activity and diagnostic detection. This intermediary allows indirect but specific measurement of LRRK2 function through its phosphorylation activity on Rubicon, enabling accurate diagnosis without directly observing LRRK2 or its complex downstream effects.
2Reliability
If LRRK2 kinase inhibitors are developed to treat PD, then therapeutic intervention is provided, but lack of bona fide LRRK2 substrates limits understanding of physiological function and target validation
Solution Approach 1:
The patent employs Rubicon protein to serve itself as a substrate for LRRK2 kinase activity. By demonstrating that Rubicon is phosphorylated by LRRK2 in physiological conditions, the system provides self-validation of the target relationship, where the substrate (Rubicon) naturally presents itself as the target of LRRK2 action, confirming both the physiological function and therapeutic relevance.
Solution Approach 2:
The patent establishes Rubicon as a multi-functional molecule that serves both as a physiological substrate of LRRK2 and as a diagnostic biomarker. This universal application allows Rubicon to fulfill multiple roles: it is involved in normal cellular processes (autophagy regulation) while simultaneously serving as a detectable marker for LRRK2 pathology and a target for therapeutic intervention.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables sensitive detection of LRRK2-related conditions through phosphorylated Rubicon protein analysis, potentially improving diagnostic accuracy and providing a therapeutic approach to slow disease progression.
Implementation Method 1
contacting the isolated proteins with an antibody that hybridises to a phosphorylated Threonine at 166 of a Rubicon protein to form a complex
Data Source
AI summary
Method of detecting phosphorylation at Threonine 166 of a Rubicon protein to identify a subject having a disease associated with Leucine-rich repeat kinase 2 (LRRK2) such as Parkinson's disease and compounds and methods for treating the same.